Immunotherapy during pregnancy — is it ever safe?

Almost never. Immune checkpoint inhibitor immunotherapy is not recommended during pregnancy. The PD-1 and PD-L1 pathway these treatments block is the same one that stops a mother’s immune system rejecting her baby. Pregnant women were excluded from every trial that established these treatments, so there is no safety evidence to rely on.

This is a rare situation, and rare is exactly why it is badly served online. Cancer diagnosed during pregnancy affects a small number of women each year, and almost nothing written for Indian patients addresses immunotherapy in that setting. What families find instead is either silence or a page written for a different treatment altogether. This page sets out what is actually known, what is not known, and who should be in the room when the decision is made.

Two different situations bring people here, and they are not the same question. In the first, a woman is pregnant and a cancer is diagnosed, and someone asks whether immunotherapy is an option. In the second, a woman is already receiving immunotherapy and discovers she is pregnant. The first is a planning decision. The second is an urgent one, and it is covered in its own section further down this page.

Before either, the ordinary eligibility question still applies. Immune checkpoint inhibitor immunotherapy is used in defined situations only — particular cancer types, particular stages, and in many settings only where a biomarker test qualifies the tumour. Most patients who ask about immunotherapy in India are told it is not part of their plan, and that answer has nothing to do with pregnancy. Pregnancy is a second filter applied after that one, not instead of it.

Where a pregnant patient has an aggressive, life-threatening cancer and there is no acceptable alternative, the question is not dismissed — it is escalated. What the medical literature holds is a small number of individual case reports, mostly in advanced melanoma, some ending with a healthy baby and some not. Numbers that small cannot tell you how likely either outcome is. So the decision is taken by a full multidisciplinary group rather than by one doctor: the medical oncologist, an obstetrician experienced in high-risk pregnancy, a neonatologist, and the tumour board, with the patient present and the reasoning written down. It is an exception made openly, not a treatment offered.

Immunotherapy on this page means immune checkpoint inhibitors as a drug class. No medicine or brand is named, nothing here is a recommendation to use any treatment, and nothing here promises that any patient will be found eligible or ineligible. At CION, immunotherapy is given as day care at our centres where it is genuinely indicated, every plan is set by a tumour board rather than by a single doctor, and any cost discussed with you is indicative, as of August 2026, and confirmed in writing before treatment starts.

There are three groups of risk. The medicine is an antibody that crosses the placenta from about the fourteenth week. Blocking the PD-1 pathway may weaken the immune tolerance that protects the pregnancy. And treating an immune reaction in the mother means steroids, and sometimes lifelong hormone replacement, which changes the pregnancy too.

The honest summary is that the concerns are mechanistic and the human evidence is thin. That combination is uncomfortable, and it is the reason the answer is a no rather than a maybe. The table below separates what is genuinely known from what is not, because the gap between those two columns is the whole decision.

One row there is easy to skim past. The steroids used to control an immune reaction are a treatment in their own right, with their own consequences — the same reason an existing diagnosis such as diabetes changes the monitoring plan for immunotherapy. In pregnancy, blood sugar, infection risk and blood pressure are already being watched, and a course of high-dose steroids lands in the middle of all three. Guideline bodies including NCCN, ASCO and ESMO address cancer treatment in pregnancy, and their guidance is revised as evidence appears; ask your team what the current position is at the time you are reading this.

Cancer in pregnancy is treatable. Surgery can be done in any trimester with obstetric input. Many chemotherapy regimens are given from the second trimester onwards. Radiotherapy is usually deferred, especially to the abdomen and pelvis. Sometimes treatment is timed around delivery. The right answer depends on the cancer, the stage and the week.

The single most important thing to know is that a cancer diagnosis during pregnancy is not, by itself, a reason to end the pregnancy. Many women are treated while pregnant and deliver healthy babies. Immunotherapy being unavailable does not mean treatment is unavailable — it means one option out of several is off the table.

No row in that table is a recommendation. It is the set of options a team should be able to talk you through, and if one of them has been ruled out you are entitled to ask why. At CION, systemic treatment is delivered as day care at our centres, response scans are coordinated at our partner imaging centres rather than performed in-house, and a pregnant patient’s plan is made together with her obstetric team rather than around it.

Tell the treating team the same day. Do not stop or change anything on your own first. The next infusion is usually held while the obstetric and oncology teams meet. You will be offered an early ultrasound to confirm and date the pregnancy, and a joint plan is made before anything else changes.

This is the situation people search for at two in the morning, and it is the one worth reading properly. Nothing about it is your fault, and an unplanned pregnancy on treatment is not a problem that has to be solved within the hour — it is a decision that needs the right people in the room within days.

1. 1

   Call your team the same day

   Your medical oncologist, or our helpline on 1800 202 8726. Say how many weeks you think you are and when your last infusion was. Do not stop any medicine on your own before you speak to someone.

2. 2

   Confirm and date the pregnancy

   An early ultrasound establishes how many weeks along you are. That number matters more than almost anything else here, because exposure in the first weeks and exposure in the third trimester are different questions.

3. 3

   The next dose is usually held

   Treatment is paused while the decision is made, not stopped for good by default. Whether it resumes, changes or ends is the outcome of the discussion, not a step taken before it.

4. 4

   One meeting, not five opinions

   Medical oncologist, an obstetrician experienced in high-risk pregnancy, a neonatologist and the tumour board review the same file together. Your own physician is included if you are being treated for another condition as well.

5. 5

   Options in writing, including the uncertainty

   You should receive the options, what is known, what is not known, and what each choice means for the cancer and for the pregnancy. Ask for it on paper. Ask what happens if you choose differently to what is suggested.

6. 6

   Closer follow-up, whatever is decided

   Growth scans and joint review through the pregnancy, and the neonatal team told before delivery so the baby can be checked and vaccination timing planned. This continues after birth.

One thing not to do is stay silent, because you expect to be judged or because you are afraid the treatment will be stopped. Teams need the information to help, and a pregnancy disclosed late is a harder problem than one disclosed early.

Effective contraception is advised for anyone who can become pregnant, throughout treatment and for a period after the last dose — commonly several months, set by the prescribing information for the medicine used. Breastfeeding is not advised in that same window. Trying to conceive later is a separate, joint decision.

• A pregnancy test before starting. Standard practice before beginning treatment for anyone who could be pregnant. It protects you, and it sets a baseline everyone can refer back to.
• Contraception during treatment and after it. Ask for the exact period that applies to the medicine you are on. It comes from that product’s prescribing information, and it is not the same for every medicine.
• Breastfeeding is not advised during or shortly after treatment. Antibodies can pass into breast milk and the effect on a newborn is not known. Raise it before the first cycle, so feeding, expressing or formula can be planned rather than improvised.
• Fertility questions belong before treatment starts. If having children later matters to you, say so at the first consultation, whatever your age. Options narrow once treatment begins.
• Conceiving later is about the cancer as much as the medicine. The risk of the disease returning, the scans still due, and any lasting thyroid or hormone problem all feed into the timing. Decide it with your oncologist and an obstetrician together.
• If the patient is male, ask anyway. Advice on conception during and after treatment differs between medicines, and the answer should come from your team rather than from a general page.

This is one of the areas where the evidence is genuinely immature, and you should be told that rather than given false precision. Long-term data on children exposed to checkpoint inhibitor immunotherapy in the womb does not exist in any useful quantity. Where a guideline gives a period, it is a precaution built on how the medicine behaves, not on outcomes measured in babies.

No single doctor should decide this alone. The assessment needs a medical oncologist, an obstetrician experienced in high-risk pregnancy, a neonatologist and a tumour board, in one conversation with you present. Nothing on this page promises that immunotherapy will or will not be offered to you.

Eligibility for immunotherapy is never settled by one factor. The cancer type, the stage and the biomarker result come first. Then fitness, which is measured rather than guessed — our page on performance status and the ECOG score explains the measure that most often decides. Pregnancy sits on top of all of that as a further constraint, in the same way that age is often blamed for a decision it did not actually make. A pregnant patient is entitled to the same structured assessment as anyone else, and to be told which specific factor closed which specific door.

These are the questions worth asking out loud. None has a standard answer, and a team that answers all seven is giving you a framework instead of a verdict.

• Is immunotherapy even an option for this cancer, at this stage, setting the pregnancy aside completely?
• How many weeks pregnant am I, and how does that change the answer?
• What would you advise if I were not pregnant, and what is being given up by not doing that?
• Can this treatment safely wait until after delivery, and what is the cost of waiting?
• Which obstetrician and which neonatologist are part of this decision, and when do they see me?
• If a serious immune reaction happened, how would it be treated in pregnancy, and what would that mean for the baby?
• What are you not certain about here, and what would change your advice?

Choosing not to have immunotherapy is a legitimate medical decision, not a failure of the plan. In pregnancy it is usually the right one, and the useful conversation is about what happens instead — which is why the alternatives table above matters more on this page than the eligibility question does.

Pregnancy is one constraint inside a larger eligibility question. These pages cover what patients ask next: how fitness is actually graded, what another existing condition changes about monitoring, how age gets misused in the same way, and where immunotherapy fits at CION at all.

• Performance Status and ECOG Score: Why It Decides Eligibility — the measure that most often settles whether immunotherapy is offered, how it is graded, and why a score recorded in hospital is not permanent.
• Immunotherapy With Diabetes — why the steroids used to treat an immune reaction are the real issue rather than the infusion itself, and how monitoring changes to account for it.
• Immunotherapy in Elderly Patients: Is Age a Barrier? — the same pattern at the other end of life, where a number on the file is allowed to stand in for an assessment nobody did.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, how response scans are coordinated with our partner imaging centres, and how costs are set out in writing.

If you are pregnant and have been told immunotherapy is your only option, or that you have no options at all, both statements deserve a second look. Bring the reports, the scan dates and your obstetrician’s details, and you will leave with the three answers written down — whether it can be given, what it would risk, and what would be used instead.

This page is general information and does not replace a consultation. It describes a treatment class only, names no medicine or brand, recommends no treatment, and does not promise that any patient will be found eligible or ineligible. Positions on cancer treatment in pregnancy, contraception and breastfeeding are drawn from NCCN, ASCO and ESMO patient-education guidance and from approved prescribing information current in August 2026, all of which are revised over time. Human safety evidence for immune checkpoint inhibitor immunotherapy in pregnancy is limited to isolated case reports; no survival figure or outcome percentage is stated or implied anywhere on this page. Every decision about treatment, its alternatives and the pregnancy belongs with your own oncology and obstetric teams.

A written second opinion, while there is still time to plan

Free, 45 minutes, reviewed by a tumour board — including the honest answer when immunotherapy is not the right treatment.